drugset / Trial / NCT07469800
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
RandomizedParallel-groupDouble-blindTreatment
Summary
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
Timeline
- Start
- 2026-04-23
- Primary completion
- 2026-08-01
- Completion
- 2027-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mazdutide | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Subject | Mazdutide | Protein / enzyme biologic | 9 mg | Subcutaneous |